Wednesday
November 29
2023

Academy for Scientific Professionals (ACSCIP)
www.acscip.org

Issue
#10



Next-Gen Quality Assurance: A Deep Dive into Integrating Artificial Intelligence in the Pharmaceutical Industry

ABM Mahfuz ul Alam, PhD

Director, Quality Operations
ACI HealthCare Limited, Sonargaon,
Narayangonj, Bangladesh

Key words:

Pharmaceutical Industry, Artificial Intelligence (AI), Quality Management System, Analytical Quality by Design (AQbD), Method Development, Rapid Testing, Design of Experiments (DoE), Statistical Tools Near-Infrared Spectroscopy (NIR), Raman Spectroscopy, Liquid Chromatography-Mass Spectrometry (LC-MS MS), Process Capability Analysis, Sigma Metrics, Advanced Quality Tools, Future Directions, Challenges, Data Privacy, Regulatory Compliance, Algorithmic Transparency, Global Data Governance

Abstract:

This article explores the transformative integration of Artificial Intelligence (AI) with advanced quality tools in the pharmaceutical industry. From the adoption of Analytical Quality by Design (AQbD) principles in method development to the application of AI in rapid testing, Design of Experiments (DoE), and statistical tools for trending and process capability analysis, a synergistic relationship emerges. The amalgamation of AI and advanced tools represents a paradigm shift, propelling quality assurance into a new frontier marked by precision, reliability, and excellence in pharmaceutical manufacturing. Despite encountering challenges such as data privacy and regulatory compliance, the industry is moving towards a future where AI is not merely a tool but a strategic partner, shaping a revolutionary landscape where the highest standards of quality are not only met but exceeded.

1. Introduction:

In an era marked by relentless pursuit of excellence in pharmaceutical manufacturing, this journal embarks on an exploration into the transformative landscape where cutting-edge technology meets the intricacies of quality assurance. The convergence of Artificial Intelligence (AI) with advanced quality tools signals a paradigm shift, offering a profound glimpse into the future of pharmaceutical quality assurance.

The overarching theme of this exploration is the integration of AI within the framework of Analytical Quality by Design (AQbD). AQbD principles, rooted in systematic and comprehensive methodologies, align seamlessly with the dynamic capabilities of AI.

As we delve into this synergy, the focus extends beyond conventional boundaries, encompassing crucial facets such as method development, rapid testing, Design of Experiments (DoE), and the application of statistical tools for trending and process capability analysis.

This journey unfolds against the backdrop of a pharmaceutical industry that recognizes the imperatives of precision, efficiency, and continuous improvement. The traditional benchmarks are no longer sufficient, and as such, the integration of AI becomes the catalyst for elevating quality assurance to unprecedented heights. The marriage of AQbD principles and AI technologies is not merely an incremental evolution; it represents a profound redefinition of the very essence of pharmaceutical quality management.

In the ensuing pages, we navigate through the intricate tapestry of methodologies where AI acts as the orchestrator, conducting a symphony of data-driven insights and analytical precision. From method development, where AI algorithms adapt and optimize, to rapid testing, revolutionized by real-time AI-driven image recognition, each aspect is a chapter in the unfolding narrative of innovation.

The Design of Experiments takes on a new dimension, guided by the learning capabilities of AI, offering a dynamic approach to exploration and optimization.

Statistical tools, infused with the analytical prowess of AI, cease to be static instruments but evolve into dynamic interpreters of complex data sets, unveiling trends and enabling a deeper understanding of process capability through sigma analyses.

This paradigm shift signifies more than technological advancement; it heralds a cultural shift in how pharmaceutical quality assurance is conceptualized and executed. It challenges the industry to embrace agility, foresight, and an unwavering commitment to excellence.

The journey into the next generation of quality assurance is not just about tools and methodologies; it is about resilience, adaptability, and the willingness to redefine benchmarks in pursuit of pharmaceutical perfection.

As we navigate this uncharted terrain, the symphony of AI and advanced quality tools becomes the anthem of a new era—one where innovation converges with tradition, and the pursuit of quality becomes an ever-evolving journey rather than a destination. Welcome to the unfolding chapters of Next-Gen Quality Assurance, where the integration of AI and pharmaceutical quality management systems is rewriting the narrative of excellence in the pharmaceutical industry.

2. Practical Implications:

2.1 Analytical Quality by Design (AQbD) and AI in Method Development:

In the dynamic realm of pharmaceuticals, ensuring the quality and reliability of analytical methods is paramount. Analytical Quality by Design (AQbD) principles serves as the guiding compass for developing these methods, ensuring they are not only effective but also robust. Now, let's delve into how the integration of Artificial Intelligence (AI) in method development is revolutionizing this process, with real-world examples highlighting its transformative impact.

2.1.1 Accelerated Drug Formulation with AI-Optimized Methods:

Consider a scenario where a pharmaceutical company is tasked with developing a new drug formulation. Traditionally, the process of method development could take months, involving numerous experiments and manual adjustments to find the optimal analytical method. However, with the application of AQbD principles and the integration of AI, this timeline is significantly compressed.

AI algorithms analyze vast datasets from initial experiments, identifying patterns and relationships between various method parameters and the desired quality outcomes. In real-time, the AI system suggests adjustments to these parameters, accelerating the optimization process. This iterative learning approach allows for quicker identification of critical method parameters, ultimately leading to the creation of a robust analytical method tailored to the specific drug formulation. The result is a streamlined and efficient development process, exemplifying the power of AI in method optimization within the framework of AQbD.

2.1.2. Real-Time Quality Monitoring in Continuous Manufacturing:

In the context of continuous manufacturing, where pharmaceuticals are produced without interruption, maintaining real-time quality control is imperative. AQbD principles guide the development of analytical methods that can adapt to the continuous production environment. When AI is introduced into this scenario, the benefits are particularly pronounced.

Imagine a production line where medicines are being manufactured continuously. AQbD principles ensure that the analytical methods used for quality control are designed with flexibility and adaptability in mind. AI, in this setting, monitors the ongoing production processes in real-time. It analyzes data from various checkpoints, constantly learning and adjusting the analytical method parameters to maintain the desired quality standards.

For example, if a critical parameter deviates from the norm, the AI system can autonomously make adjustments to the analytical method, ensuring that the quality of the pharmaceutical product is not compromised. This real-time adaptability, guided by the principles of AQbD and facilitated by AI, exemplifies a proactive approach to quality control in the ever-evolving landscape of continuous manufacturing.

In these real-world examples, the synergy of AQbD principles and AI in method development showcases not only efficiency and adaptability but also a paradigm shift towards a future where pharmaceutical quality assurance is agile, data-driven, and continuously optimized.

2.2 Rapid Testing and AI in the Pharmaceutical Industry:

In the fast-paced world of pharmaceutical manufacturing, the need for rapid testing is more critical than ever. Traditional testing methods, while reliable, often involve time-consuming processes that may delay the release of vital medications. The integration of Artificial Intelligence (AI) into rapid testing is transforming this landscape, ensuring swift and accurate assessments that align with the industry's stringent quality standards. Let's explore this synergy with two practical examples.

2.2.1. Automated Visual Inspection for Tablet Formulations:

Consider a pharmaceutical company responsible for manufacturing a widely used tablet formulation. In traditional quality control processes, visual inspection of each tablet for defects could be labor-intensive and time-consuming. With the integration of AI-driven image recognition, this manual process is revolutionized.

Cameras equipped with AI algorithms are strategically placed along the production line. As tablets move through the line, the AI system rapidly captures and analyzes images of each tablet's surface. The image recognition technology quickly identifies visual defects such as cracks, discoloration, or irregularities that may not be easily detectable by the human eye.

In real-time, the AI system processes this visual data, flagging any tablets with defects. Automated reject mechanisms are triggered to remove flawed tablets from the production line, ensuring that only tablets meeting the highest visual quality standards proceed for further processing. This not only accelerates the testing process but also significantly enhances accuracy, reducing the likelihood of human oversight and ensuring that only top-quality tablets reach the market.

2.2.2. AI-Enhanced Spectroscopic Analysis for Liquid Pharmaceuticals:

For liquid pharmaceuticals, ensuring the right chemical composition is crucial. Traditionally, spectroscopic analysis methods could be time-consuming, requiring meticulous laboratory procedures. AI steps in to streamline this process.

Imagine a pharmaceutical company producing a liquid formulation. AI is integrated with cutting-edge spectroscopic tools such as Near-Infrared Spectroscopy (NIR). As liquid batches move through the production line, the NIR spectroscopy system quickly analyzes the chemical composition of each sample.

The AI algorithms behind the spectroscopic analysis have been trained on vast datasets, enabling them to identify the ideal chemical signatures for the specific liquid formulation. Any deviations from this ideal signature are promptly flagged. The real-time analysis allows for immediate corrective actions, whether it be adjusting the formulation in the production process or conducting additional tests to verify the composition.

This AI-enhanced spectroscopic analysis not only accelerates the testing of liquid pharmaceuticals but also adds a layer of precision that goes beyond traditional methods. It exemplifies how the marriage of AI and advanced analytical tools can revolutionize quality control in the pharmaceutical industry.

2.2.3. Real-time Monitoring of Parenteral Solution Fill Levels:

In the production of parenteral solutions, where precise fill levels are crucial, rapid testing is indispensable. Traditionally, ensuring accurate fill levels involves periodic sampling and manual measurement, which may not capture variations in real-time. AI transforms this process into a dynamic and continuous monitoring system.

AI-powered cameras and sensors are strategically placed along the production line to monitor the fill levels of parenteral solution vials. The AI algorithms analyze the visual data in real-time, detecting any deviations from the specified fill levels. If an anomaly is identified, the system can trigger an immediate response, such as adjusting the filling mechanism or diverting the affected vials for further inspection.

This real-world application of AI in rapid testing ensures that any deviations in fill levels are swiftly addressed, maintaining the integrity and safety of the pharmaceutical product. The continuous monitoring aspect of AI-driven rapid testing provides a level of vigilance that surpasses traditional methods, where occasional sampling may miss transient variations.

2.2.4. AI-Enhanced Particle Detection in Injectable Manufacturing:

In the production of injectable pharmaceuticals, ensuring the absence of foreign particles is critical for patient safety. Traditional methods of particle inspection involve manual sampling and microscopic examination, a time-intensive process that may not catch every irregularity. AI offers a transformative solution to this challenge.

AI-driven image recognition systems, equipped with advanced pattern analysis capabilities, are employed to scan each vial or ampule for the presence of particles. The system can differentiate between normal particles introduced during the manufacturing process (such as cosmetic particles) and abnormal particles that may pose a risk to the product's safety.

For instance, if an irregular particle is detected, the AI system can instantly flag the affected vial for further investigation. This real-time analysis not only expedites the testing process but also enhances the accuracy of particle detection. By leveraging AI, pharmaceutical manufacturers can ensure that injectable products are free from contaminants, meeting stringent quality standards and regulatory requirements.

In all these examples, the symbiosis of AI and rapid testing technologies showcases a paradigm shift in the efficiency and accuracy of quality control processes within the pharmaceutical manufacturing landscape. This not only aligns with the industry's demand for speed and reliability but also ensures that the products reaching patients are of the highest quality.

2.3. Design of Experiments (DoE) and Statistical Tools in Pharmaceutical Research:

In the intricate landscape of pharmaceutical research, the application of Design of Experiments (DoE) combined with Artificial Intelligence (AI) and statistical tools has become a catalyst for innovation. This section delves into two practical examples showcasing how this synergistic approach enhances efficiency, enabling pharmaceutical researchers to optimize processes and formulations with unparalleled precision.

2.3.1. Formulation Optimization for Oral Solid Dosage Forms:

Imagine a pharmaceutical company aiming to develop an oral solid dosage form, such as a tablet, with improved dissolution characteristics. Traditionally, researchers might conduct a series of experiments, tweaking factors like excipient composition, compression force, and coating thickness to observe their impact on dissolution rates. However, with the integration of AI and statistical tools into DoE, this process becomes not only faster but more insightful.

AI algorithms, working in tandem with statistical tools, can identify complex interactions between various factors affecting dissolution. Researchers set up experiments where these factors are systematically varied, and AI analyzes the outcomes in real-time. As the AI system iteratively learns from each experiment, it suggests the most promising combinations of factors for the next round.

For instance, if the initial experiments reveal that a specific combination of excipients and compression force leads to optimal dissolution, the AI system can guide subsequent experiments to further refine this combination. The result is a streamlined and efficient formulation optimization process. The precision offered by the AI-driven DoE approach allows researchers to arrive at an optimized formulation with fewer experiments, saving time and resources.

*2.3.2. Process Optimization in Continuous Manufacturing of Pharmaceuticals:***

In the context of continuous manufacturing, where pharmaceuticals are produced without interruption, optimizing processes becomes a complex challenge. Suppose a pharmaceutical company is transitioning from traditional batch manufacturing to a continuous process for a specific drug formulation. AI-driven DoE and statistical tools prove invaluable in this scenario.

The AI system, integrated with statistical tools, can design experiments to explore multifactorial interactions in real-time during continuous production. For instance, factors like temperature, flow rates, and reaction times are varied systematically, and the AI system analyzes how these variations impact the quality and yield of the product. This continuous feedback loop allows for dynamic adjustments to the manufacturing process, ensuring optimal performance.

If, for example, a certain combination of parameters leads to a higher yield with consistent quality, the AI system can adapt the ongoing process accordingly. This real-time optimization, facilitated by AI-driven DoE, ensures that the continuous manufacturing process operates at peak efficiency, producing pharmaceuticals with the desired attributes.

In both practical examples, the synergy of AI with DoE and statistical tools demonstrates a shift towards a more efficient and insightful approach in pharmaceutical research. This integration empowers researchers to navigate the complexity of multifactorial interactions with unprecedented precision, accelerating the optimization of processes and formulations in a manner that was once considered challenging with traditional methods.

2.4. Process Capability Analysis and Sigma Metrics in Pharmaceutical Manufacturing:

In the realm of pharmaceutical manufacturing, the integration of Artificial Intelligence (AI) into process capability analysis has ushered in a new era of quality control. This section explores two practical examples where AI contributes to real-time monitoring, proactive adjustments, and the enhancement of sigma metrics, ensuring that pharmaceutical processes not only meet compliance standards but strive for excellence.

2.4.1. Real-Time Monitoring and Adjustment in Continuous Tablet Compression:

Consider a scenario in tablet manufacturing where continuous compression technology is employed to produce tablets without interruption. In such a dynamic environment, maintaining consistent quality is paramount. AI-driven process capability analysis continuously monitors critical parameters such as compression force, dwell time, and tablet hardness in real-time.

The AI system is programmed to recognize patterns and trends in the data as it streams from the compression process. If, for example, the compression force deviates beyond the specified limits, the AI system detects this anomaly and triggers a real-time alert. The proactive nature of AI enables quick adjustments to the compression process, ensuring that tablets consistently meet quality standards.

As a practical example, if the real-time analysis indicates that a particular combination of compression force and dwell time leads to tablets with better hardness, the AI system can autonomously adjust the parameters to optimize tablet quality. This continuous feedback loop, facilitated by AI, not only maintains process capability within defined limits but also allows for on-the-fly improvements, aligning with the principles of Six Sigma.

2.4.2. Six Sigma Analysis for Injectable Manufacturing:

In the production of injectable pharmaceuticals, where precision and consistency are critical, Six Sigma analysis becomes a powerful tool for quality control. Traditional approaches may involve periodic sampling and manual data analysis, but the integration of AI elevates this process to a new level.

AI continuously monitors key parameters in the injectable manufacturing process, such as fill volumes, particle counts, and container closure integrity. The system analyzes vast datasets in real-time, identifying variations and deviations from the desired specifications. If, for instance, the fill volume begins to fluctuate, the AI system intervenes to bring it back within the defined limits.

Here's where Six Sigma analysis comes into play. AI, with its ability to analyze large datasets, calculates the sigma metrics – a measure of process capability. If the process consistently operates within the defined limits and exhibits minimal variability, it achieves a high sigma value (e.g., 6 sigma), indicating an exceptionally capable and reliable process.

Practically, this means that the injectable manufacturing process, guided by AI-driven insights, not only adheres to quality standards but strives for excellence represented by high sigma metrics. This integration ensures that the production of injectables consistently meets stringent quality requirements, minimizing defects and enhancing overall process capability.

In these practical examples, the marriage of AI with process capability analysis and sigma metrics showcases a shift towards a more advanced and proactive approach in pharmaceutical manufacturing. AI-driven real-time monitoring and adjustments not only maintain process capability within defined limits but also contribute to achieving high sigma metrics, reflecting a commitment to excellence in quality control processes.

2.5. Advanced Quality Tools - NIR, Raman Spectroscopy, LC-MS MS in Pharmaceutical Quality Control:

In the pharmaceutical industry, the integration of Artificial Intelligence (AI) with advanced quality tools such as Near-Infrared Spectroscopy (NIR), Raman Spectroscopy, and Liquid Chromatography-Mass Spectrometry (LC-MS MS) represents a quantum leap in quality control and management. This section explores two practical examples showcasing how AI enhances the capabilities of these tools, providing unprecedented insights into the molecular composition, impurity profiles, and formulation characteristics of pharmaceutical products.

2.5.1. Enhanced Formulation Analysis with Raman Spectroscopy and AI:

Imagine a pharmaceutical company developing a complex drug formulation. Traditionally, analyzing the molecular structure and composition of such formulations might involve time-consuming and resource-intensive processes. With the integration of AI and Raman Spectroscopy, this analysis becomes not only efficient but also highly insightful.

Raman Spectroscopy, a technique that probes molecular vibrations, is employed to analyze the formulation. The resulting spectra, rich with information about the molecular bonds and structures, are complex and require sophisticated analysis. This is where AI steps in. AI algorithms, trained on a vast dataset of Raman spectra and corresponding formulation characteristics, can decipher intricate patterns within the spectra.

In a practical application, if the Raman spectra of a new formulation are obtained, the AI system can rapidly and accurately identify specific molecular features, providing insights into the composition and potential impurities. For instance, if an unexpected peak is detected, the AI system can cross-reference it with known impurity profiles, alerting researchers to potential issues in real-time.

This integration of AI with Raman Spectroscopy not only expedites the analysis process but also enhances the specificity and sensitivity of impurity detection. It allows pharmaceutical researchers to gain a comprehensive understanding of the formulation's molecular structure, enabling informed decisions regarding optimization or adjustments to meet quality standards.

2.5.2. Real-Time Impurity Detection in Continuous Manufacturing Using LC-MS MS and AI:

In continuous pharmaceutical manufacturing, maintaining a high level of quality control is a complex challenge. Traditional methods of detecting impurities in products involve periodic sampling and offline analysis. However, with the integration of AI and Liquid Chromatography-Mass Spectrometry (LC-MS MS), real-time impurity detection becomes a reality.

LC-MS MS is a powerful technique for separating and identifying compounds in a sample. In a continuous manufacturing setting, this tool is coupled with AI to monitor the product stream in real-time. As pharmaceutical products flow through the system, the AI system analyzes the complex mass spectra generated by LC-MS MS, identifying peaks and patterns associated with impurities.

In a practical example, if an unexpected peak appears in the mass spectra, the AI system can swiftly recognize it as a potential impurity. The system then initiates corrective actions, such as adjusting process parameters or diverting the affected product for further analysis. This real-time intervention ensures that only products meeting the highest quality standards continue through the manufacturing process.

The integration of AI with LC-MS MS in continuous manufacturing not only enhances the speed of impurity detection but also ensures a proactive and adaptive approach to quality control. It exemplifies how advanced quality tools, when augmented by AI, provide a level of precision and real-time decision-making capability that is paramount in ensuring the quality and safety of pharmaceutical products.

In these practical examples, the synergy of AI with advanced quality tools (Raman Spectroscopy, LC-MS MS) demonstrates a paradigm shift in pharmaceutical quality control and management. The enhanced sensitivity, specificity, and real-time capabilities provided by AI-driven analysis elevate these tools to new heights, empowering pharmaceutical companies to produce products that meet the highest standards of quality and safety.

3. Challenges and Future Directions:

The integration of Artificial Intelligence (AI) and advanced quality tools into the pharmaceutical industry represents a transformative leap forward, promising unparalleled advancements in efficiency and product quality.

However, this integration is not without its challenges. This section explores the current challenges and envisions future directions as the industry navigates this revolutionary landscape.

3.1. Challenges:

3.1.1. Data Privacy Concerns:

Issue: The utilization of AI in pharmaceutical processes involves handling vast amounts of sensitive data, including patient information, formulation details, and manufacturing parameters. Ensuring the privacy and security of this data is a paramount concern.

Challenge: Striking a balance between leveraging the power of AI for analysis and maintaining strict data privacy standards is a significant challenge. Implementing robust encryption and access control measures becomes imperative to safeguard sensitive information.

3.1.2. Regulatory Compliance:

Issue: The pharmaceutical industry is subject to stringent regulatory frameworks that dictate the standards for manufacturing, testing, and quality assurance. Integrating AI into these processes necessitates compliance with existing regulations.

Challenge: Navigating the complex regulatory landscape to ensure that AI-driven processes adhere to current standards poses a challenge. Regulatory bodies are evolving to accommodate technological advancements, but a clear and standardized framework is still emerging.

3.1.3. Algorithmic Transparency:

Issue: The "black-box" nature of some AI algorithms can be a barrier to understanding the decision-making process. Lack of transparency may hinder the industry's ability to trust and validate the results generated by AI systems.

Challenge: Developing and adopting AI algorithms that are not only effective but also transparent is crucial. Striking a balance between complexity and interpretability is a challenge that researchers and developers must address.

3.2. Future Directions:

3.2.1. Unified Regulatory Frameworks:

Vision: The future sees the establishment of unified regulatory frameworks that specifically address the integration of AI into pharmaceutical processes. Clear guidelines and standards will provide a roadmap for companies to ensure compliance and facilitate innovation.

3.2.2. Ethical AI in Pharma:

Vision: The industry is moving towards an era where ethical considerations in AI use become ingrained in the development process. Establishing ethical guidelines for data usage, patient privacy, and algorithmic decision-making will be critical.

3.2.3. Interdisciplinary Collaboration:

Vision: Bridging the gap between pharmaceutical expertise and AI proficiency is essential for successful integration. Interdisciplinary collaboration between pharmacists, chemists, biologists, and AI experts will drive innovation and ensure that AI solutions align with industry needs.

3.2.4. Explainable AI:

Vision: The future of AI in pharmaceuticals involves the development of explainable AI models. Ensuring that the decision-making process of algorithms is transparent and understandable will enhance trust and facilitate regulatory compliance.

3.2.5. Global Data Governance:

Vision: Collaboration on a global scale to establish comprehensive data governance standards will address data privacy concerns. This includes defining how data is shared, stored, and used across borders, ensuring a harmonized approach to privacy.

3.2.6. Education and Training:

Vision: As AI becomes an integral part of pharmaceutical processes, investing in education and training programs is crucial. Building a workforce well-versed in both pharmaceutical science and AI technologies will be essential for successful implementation.

3.2.7. AI as a Strategic Partner:

Vision: The future sees AI evolving beyond being a tool to becoming a strategic partner in quality assurance. AI systems will not only analyze data but actively contribute to decision-making, providing insights that shape the direction of pharmaceutical development and manufacturing.

In conclusion, the challenges associated with the integration of AI and advanced quality tools in the pharmaceutical industry are substantial but not insurmountable. Addressing these challenges will pave the way for a future where AI is not just a tool but an indispensable strategic partner, driving efficiency, innovation, and unparalleled product quality in the pharmaceutical landscape.

4. Conclusion:

The exploration of integrating Artificial Intelligence (AI) with advanced quality tools in the pharmaceutical sector signifies a pivotal transformation. Embracing Analytical Quality by Design (AQbD) in method development, rapid testing, Design of Experiments (DoE), and statistical tools for trending and process capability analysis, the symbiosis with AI propels the realm of quality assurance into uncharted territory. As we traverse this cutting-edge landscape, the fusion of AI and advanced tools emerges as synonymous with precision, reliability, and excellence in pharmaceutical manufacturing. This integration is not a mere evolutionary step; it is a revolutionary leap, shaping a future where surpassing the highest standards of quality is not just an aspiration but a tangible reality.

5. References:

1. ABM Mahfuz ul Alam, Nilufar Nahar, M Iqbal Rouf Mamun, Mohammad Shoeb, "A Qbd Based RP - HPLC Method Development and Validation for Quantification ff Pregabalin Capsules", International Journal of Science and Research (IJSR), Volume 12 Issue 11, November 2023, pp. 948-955, https://dx.doi.org/10.21275/SR231112082256, https://www.ijsr.net/getabstract.php?paperid=SR231112082256
2. Alam, D.A.M. ul and Shilpi, S. (2023). MITIGATING RISKS AND ENSURING COMPLIANCE : HUMAN FACTORS IN PHARMACEUTICAL QMS. 0 edition ed. [online] Amazon. ACSCIP, Dhaka, Bangladesh. Available at: https://www.amazon.co.jp/MITIGATING-RISKS-ENSURING-COMPLIANCE-PHARMACEUTICAL-ebook/dp/B0C817GDFD [Accessed 26 Nov. 2023].
3. Alam , A.M. ul (2018). Method Development and Quantification for Some Non Pharmacopeial drugs. University of Dhaka, Dhaka, [online] 651.1 ALM. Available at: http://dulis.library.du.ac.bd/index.php [Accessed 26 Nov. 2023]. PhD Thesis .
4. Alam , A.M. ul , Nahar , N., Mosihuzzaman, M. and Shilpi , S. (2020). CONSTITUENTS OF THE ESSENTIAL OIL FROM AQUILARIA AGALLOCHA ROXB BY GC-MS AND ITS CYTOTOXIC ACTIVITIES. EUROPEAN JOURNAL OF PHARMACEUTICALAND MEDICAL RESEARCH, [online] 7(12), pp.105–109. Available at: https://www.ejpmr.com/home/abstract_id/7610 [Accessed 26 Nov. 2023